Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.

ABSTRACT:

Background and purpose

Rosiglitazone is an anti-diabetic drug improving insulin sensitivity and glucose uptake in skeletal muscle and adipose tissues. However, several recent clinical trials suggest that rosiglitazone can increase the risk of cardiovascular ischaemia, although other studies failed to show such risks. Therefore, the effects of rosiglitazone on the coronary circulation and any potential vascular targets need to be elucidated. Here, we show that the vascular isoform of the ATP-sensitive K(+) (K(ATP) ) channel is inhibited by rosiglitazone, impairing physiological regulation of the coronary circulation.

Experimental approach

The K(IR) 6.1/SUR2B channel was expressed in HEK293 cells and studied in whole-cell and inside-out patch configurations. The Langendorff he

SUBMITTER: Yu L 

PROVIDER: S-EPMC3246668 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature